The global digital diabetes management market size valued at USD 6.3 billion in 2018 and is expected to grow at a compound annual growth rate (CAGR) of 19.4% from 2019 to 2026. Robust growth of the market is majorly attributed to increasing technological advancements and innovations in the field. The number of smartphones apps available for disease management has increased over the last few years and there are several apps available on web-based app stores that can help patients monitor their blood glucose levels.
Key factors driving the market include growing geriatric population, increasing disease incidence, and rising healthcare spending. According to the International Diabetes Federation, approximately 425 million adults were living with diabetes in 2017 and this number is expected to reach 629 million in 2045. As digital technology is continuously advancing, the market is expected to witness a wide range of innovations in the field of diabetes, which could have the potential to change the way patients manage this disease.
Rapidly changing lifestyles and unhealthy dietary habits are contributing to the rise in prevalence of diabetes worldwide. Obesity is also one of the major factors contributing to diabetes. According to WHO, more than 650 million people were obese in 2016 and this number is expected to grow further during the forecast period. The market for diet and weight management apps is showing great potential with increasing obese population, coupled with increasing awareness about the same.
Diabetes is a clinical condition wherein the inability of the pancreas to produce insulin causes increased glucose levels in the body. Diabetics face many daily challenges such as dietary restrictions and regular administering of insulin. The anytime-anywhere nature of digital technology enables patients to address their health issues by connecting with the healthcare team and sharing data. This is creating a digital ecosystem of data driven tools that can connect patients and their care team for better management of diabetes.
Based on product, the market has been segmented into smart glucose meter, continuous blood glucose monitoring systems, smart insulin pens, smart insulin pumps, and apps. Continuous blood glucose monitoring systems held the largest market share of just under 40.0% in 2018 owing to their compatibility with smart devices that serve as a display device. Moreover, they can also be set to send custom alerts to patients when certain glucose thresholds are reached.
The smart insulin pen segment is expected to grow at the highest CAGR of 22.0% over the forecast period. The high growth rate of the segment is majorly attributed to increasing number of product launches in the field of digital healthcare and introduction of artificial intelligence. Many market players are focusing on innovating smart insulin pen to stay ahead of the competition. For instance, Companion Medical’s InPen system, which was launched in December 2017, is the first FDA-approved solution that can connect with smartphone apps.
By apps, the market is divided into digital diabetes management apps and apps for weight and diet management. The former segment captured the largest market share in 2018 and was valued at USD 173.0 million that year. The growth of the segment is majorly attributed to increasing preference of patients for these apps. Such apps allow continuous monitoring of blood glucose levels and are widely used by the elderly population as well.
The weight and diet management apps segment also holds a considerable share in the market owing to increasing awareness of chronic diseases such as diabetes and its related complications. These apps use advanced digital data analytics to allow healthcare professionals to provide patients with the best possible solution. Key factors driving this segment are improved health outcomes, reduction of error rates, and declining healthcare costs. This segment is expected to register a CAGR of 22.0% over the forecast period.
Based on type, the digital diabetes management market has been segmented into wearable and handheld devices. Wearable devices held the largest market share and the segment is expected to exhibit the fastest CAGR of 19.6% over the forecast period. The growth of the market is majorly attributed to technological advancements such as advent of artificial intelligence, growing adoption self-administering insulin delivery devices in diabetes management, and launch of new products such as closed-loop pump systems and smart insulin patches.
The handheld device segment accounted for a share of over 43.0% in 2018 and poised to witness stead growth over the forecast period. This is primarily attributed to new product launches in the field. For instance, in June 2018, Insulet Corporation received FDA approval for its handheld dash system. The device is a touchscreen personal diabetes manager with Wi-Fi connectivity that allows the software to be remotely updated.
Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East and Africa. North America dominated the market in 2018 driven by increasing penetration of smart consumer devices and innovation in AI-based services. Furthermore, the region is in the next stage of digitization of concepts such Internet of Things, big data, machine learning, and robotics. Thus, these digital technologies are expected to propel the regional market during the forecast period. Europe is also expected to capture a considerable share over the forecast period owing to novel product launches and presence of key players in the region.
Asia Pacific is expected to witness exponential growth over the forecast period owing to new product launches and a large diabetes population base. Currently, over 230 million people are living with diabetes, accounting for approximately 55.0% of the global population. The region is also witnessing many product launches. For instance, in May 2019, Roche Diabetes Care India introduced its Integrated Diabetes Management Solution (IDMS) program in India with the launch of Accu-Chek Instant blood glucose monitoring (BGM) system and the My Sugar app. The combination marks the entry of next-generation BGM systems.
Some of the prominent players are Abbott Laboratories; Medtronic plc; F. Hoffmann-La Roche Ltd; Bayer AG; Lifescan, Inc.; Dexcom, Inc.; Sanofi; Insulet Corporation; Ascensia Diabetes Care Holdings Ag; and B Braun Melsungen AG. These players are focused on adopting new technologies and introducing advanced products in order to offer better services to their customers and to strengthen their presence in the market. For instance, in June 2018, Medtronic Plc, along with its technology partner IBM Watson Health, launched the Sugar. IQ smart diabetes assistant. This intelligent app is designed to improve daily diabetes management. Some of the prominent players in the digital diabetes management market include:
Abbott Laboratories
Medtronic plc
F. Hoffmann-La Roche Ltd
Bayer AG
Lifescan, Inc.
Dexcom, Inc.
Sanofi
Insulet Corporation
Ascensia Diabetes Care Holdings Ag
B Braun Melsungen AG
Report Attribute |
Details |
Market size value in 2020 |
USD 9.2 billion |
Revenue forecast in 2026 |
USD 27.0 billion |
Growth Rate |
CAGR of 19.8% from 2019 to 2026 |
Base year for estimation |
2018 |
Historical data |
2015 - 2017 |
Forecast period |
2019 - 2026 |
Quantitative units |
Revenue in USD million and CAGR from 2019 to 2026 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, type, app, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; China; Japan; India; Australia; South Korea; Mexico; Brazil; Colombia; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Abbott Laboratories; Medtronic plc; F. Hoffmann-La Roche Ltd; Bayer AG; Lifescan, Inc.; Dexcom, Inc.; Sanofi; Insulet Corporation; Ascensia Diabetes Care Holdings Ag; B Braun Melsungen AG |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels as well as provides an analysis on the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global digital diabetes management market report on the basis of product, type, app, and region:
Product Outlook (Revenue, USD Million, 2015 - 2026)
Smart glucose meter
Continuous blood glucose monitoring system
Smart insulin pens
Smart insulin pumps
Apps
App Outlook (Revenue, USD Million, 2015 - 2026)
Digital diabetes management apps
Weight & diet management apps
Type Outlook (Revenue, USD Million, 2015 - 2026)
Wearable devices
Handheld devices
Regional Outlook (Revenue, USD Million, 2015 - 2026)
North America
The U.S.
Canada
Europe
Germany
The U.K.
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
b. The global digital diabetes management market size was estimated at USD 7.6 billion in 2019 and is expected to reach USD 9.2 billion in 2020.
b. The global digital diabetes management market is expected to grow at a compound annual growth rate of 19.8% from 2019 to 2026 to reach USD 27.0 billion by 2026.
b. North America dominated the digital diabetes management market with a share of 39.3% in 2019. This is attributable to the increasing penetration of smart consumer devices and innovation in AI-based services.
b. Some key players operating in the digital diabetes management market include Abbott Laboratories; Medtronic plc; F. Hoffmann-La Roche Ltd; Bayer AG; Lifescan, Inc.; Dexcom, Inc.; Sanofi; Insulet Corporation; Ascensia Diabetes Care Holdings Ag; and B Braun Melsungen AG.
b. Key factors that are driving the market growth include increasing technological advancements and rising FDA approval for innovative products.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.